// Auto-generated - do not edit
export const substanceName = "Prazepam";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Prazepam.md","displayName":"DrugBank","size":15317},{"id":"protestkit","fileName":"PROTESTKIT - Prazepam.json","displayName":"Protest Kit","size":3877},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Prazepam.md","displayName":"TripSit Factsheets","size":896},{"id":"wikipedia","fileName":"WIKIPEDIA - Prazepam.md","displayName":"Wikipedia","size":4972}];
export const contents: Record<string, string> = {
  "drugbank": `# Prazepam
*Source: https://go.drugbank.com/drugs/DB01588*

## Overview

### Description

This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.

### Background

Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.

### Indication

For the treatment of anxiety disorders.

### Pharmacodynamics

Prazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Benzodiazepines may be habit-forming (causing mental or physical dependence), especially when taken for a long time or in high doses.

### Mechanism of Action

GABA(A) Receptor
Positive allosteric modulator
GABA(A) Receptor Benzodiazepine Binding Site
Ligand

### Metabolism

Hepatic.

### Half-life

36-200 hours

### Toxicity

Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Prazepam is combined with 1,2-Benzodiazepine.
Abametapir
The serum concentration of Prazepam can be increased when it is combined with Abametapir.
Acetazolamide
The risk or severity of CNS depression can be increased when Acetazolamide is combined with Prazepam.
Acetophenazine
The risk or severity of CNS depression can be increased when Acetophenazine is combined with Prazepam.
Agomelatine
The risk or severity of CNS depression can be increased when Prazepam is combined with Agomelatine.

### Food Interactions

Avoid alcohol.
Avoid grapefruit products.
Limit caffeine intake.
Take with food.

## Chemical Information

**DrugBank ID:** DB01588

**Synonyms:** Prazepam
Prazepamum

**Chemical Formula:** C
19
H
17
ClN
2
O

**SMILES:** ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1

**Weight:** Average: 324.804
Monoisotopic: 324.102940883

**IUPAC Name:** 7-chloro-1-(cyclopropylmethyl)-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

4

### Phase 0

0

### Phase 1

0

### Phase 2

0

### Phase 3

0

### Phase 4

0

### Summary

Prazepam
is a benzodiazepine used to manage more severe forms of anxiety disorders.

### Generic Name

Prazepam

### DrugBank Accession Number

DB01588

### Groups

Approved, Illicit

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Prazepam (DB01588)
×
Close

### External IDs

W 4020

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Management of
Anxiety
••••••••••••
Create Account
••••••••• ••••••
Management of
Anxiety disorders
••••••••••••
Create Account
•••••• •••••••
••••••••• ••••••
Induction of
Muscle relaxation
••••••••••••
Create Account
••••••••• ••••••
Create Account

### Mechanism of action

Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.
Target
Actions
Organism
A
GABA(A) Receptor
positive allosteric modulator
Humans
A
GABA(A) Receptor Benzodiazepine Binding Site
ligand
Humans
U
Translocator protein
modulator
Humans

### International/Other Brands

Centrax
/
Demetrin
/
Lysanxia
/
Sedapran
/
Trepidan

### ATC Codes

N05BA11 — Prazepam
N05BA — Benzodiazepine derivatives
N05B — ANXIOLYTICS
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Anti-Anxiety Agents
Benzazepines
Benzodiazepines and benzodiazepine derivatives
Benzodiazepinones
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 Substrates
GABA Agents
GABA Modulators
Heterocyclic Compounds, Fused-Ring
Nervous System
Neurotransmitter Agents
Psycholeptics
Psychotropic Drugs
Tranquilizing Agents

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives
/
Benzene and substituted derivatives
/
Aryl chlorides
/
Tertiary carboxylic acid amides
/
Lactams
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organochlorides
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 3 more
Substituents
1,4-benzodiazepine
/
Alpha-amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Hydrocarbon derivative
/
Imine
/
Ketimine
/
Lactam
/
Monocyclic benzene moiety
/
Organic 1,3-dipolar compound
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organochloride
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Propargyl-type 1,3-dipolar organic compound
/
Tertiary carboxylic acid amide
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzodiazepine (
CHEBI:8362
)

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Benzodiazepines

### Sub Class

1,4-benzodiazepines

### Direct Parent

1,4-benzodiazepines

### Alternative Parents

Alpha amino acids and derivatives
/
Benzene and substituted derivatives
/
Aryl chlorides
/
Tertiary carboxylic acid amides
/
Lactams
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organochlorides
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 3 more

### Substituents

1,4-benzodiazepine
/
Alpha-amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Hydrocarbon derivative
/
Imine
/
Ketimine
/
Lactam
/
Monocyclic benzene moiety
/
Organic 1,3-dipolar compound
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organochloride
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Propargyl-type 1,3-dipolar organic compound
/
Tertiary carboxylic acid amide
show 16 more

### Molecular Framework

Aromatic heteropolycyclic compounds

### External Descriptors

benzodiazepine (
CHEBI:8362
)

### Affected organisms

Humans and other mammals

### UNII

Q30VCC064M

### CAS number

2955-38-6

### InChI Key

MWQCHHACWWAQLJ-UHFFFAOYSA-N

### InChI

InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2

### External Links

Human Metabolome Database
HMDB0015527
KEGG Drug
D00470
KEGG Compound
C07366
PubChem Compound
4890
PubChem Substance
46505417
ChemSpider
4721
RxNav
8627
ChEBI
8362
ChEMBL
CHEMBL969
ZINC
ZINC000000001971
Therapeutic Targets Database
DAP000689
PharmGKB
PA164776668
Wikipedia
Prazepam

### Human Metabolome Database

HMDB0015527

### KEGG Drug

D00470

### KEGG Compound

C07366

### PubChem Compound

4890

### PubChem Substance

46505417

### ChemSpider

4721

### RxNav

8627

### ChEBI

8362

### ChEMBL

CHEMBL969

### ZINC

ZINC000000001971

### Therapeutic Targets Database

DAP000689

### PharmGKB

PA164776668

### Wikipedia

Prazepam

### Packagers

Physicians Total Care Inc.

### Dosage Forms

Form
Route
Strength
Tablet
Oral
10 mg/1
Tablet
Oral
20 mg
Solution / drops
Oral
Tablet
Oral
Tablet
Oral
10 MG

### Prices

Unit description
Cost
Unit
Doral 15 mg tablet
3.41USD
tablet
Doral 7.5 mg tablet
3.37USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
145-146 °C
PhysProp
logP
3.73
HANSCH,C ET AL. (1995)

### Predicted Properties

Property
Value
Source
Water Solubility
0.00399 mg/mL
ALOGPS
logP
3.68
ALOGPS
logP
3.86
Chemaxon
logS
-4.9
ALOGPS
pKa (Strongest Basic)
3.06
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
2
Chemaxon
Hydrogen Donor Count
0
Chemaxon
Polar Surface Area
32.67 Å
2
Chemaxon
Rotatable Bond Count
3
Chemaxon
Refractivity
91.75 m
3
·mol
-1
Chemaxon
Polarizability
34.77 Å
3
Chemaxon
Number of Rings
4
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
Yes
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9821
Blood Brain Barrier
+
0.9934
Caco-2 permeable
+
0.6922
P-glycoprotein substrate
Substrate
0.6631
P-glycoprotein inhibitor I
Inhibitor
0.7452
P-glycoprotein inhibitor II
Inhibitor
0.6438
Renal organic cation transporter
Inhibitor
0.6625
CYP450 2C9 substrate
Non-substrate
0.7317
CYP450 2D6 substrate
Non-substrate
0.8332
CYP450 3A4 substrate
Substrate
0.7471
CYP450 1A2 substrate
Inhibitor
0.861
CYP450 2C9 inhibitor
Inhibitor
0.5153
CYP450 2D6 inhibitor
Non-inhibitor
0.7477
CYP450 2C19 inhibitor
Inhibitor
0.7793
CYP450 3A4 inhibitor
Inhibitor
0.6455
CYP450 inhibitory promiscuity
High CYP Inhibitory Promiscuity
0.7974
Ames test
Non AMES toxic
0.8623
Carcinogenicity
Non-carcinogens
0.8138
Biodegradation
Not ready biodegradable
1.0
Rat acute toxicity
1.8779 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9819
hERG inhibition (predictor II)
Non-inhibitor
0.5471
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-002e-3090000000-85ecde8de7c9923c1afc
Mass Spectrum (Electron Ionization)
MS
splash10-00r5-3391000000-0113e86cca51d223d412
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-004i-1009000000-e61e9bea3435d446fd4d
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00di-1059000000-2b02f9749609ac7c64c8
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-004j-0097000000-ba108e7b71d771b6179c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0kw0-2291000000-46e22d4a73d9ea5f0050
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0159-1192000000-654e0ae15fc2404af461
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-001l-9240000000-b963167a70155e867ef6
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
180.7325904
predicted
DarkChem Lite v0.1.0
[M-H]-
170.41753
predicted
DeepCCS 1.0 (2019)
[M+H]+
180.7889904
predicted
DarkChem Lite v0.1.0
[M+H]+
172.77553
predicted
DeepCCS 1.0 (2019)
[M+Na]+
180.9263904
predicted
DarkChem Lite v0.1.0
[M+Na]+
179.61446
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Substrate

### Curator comments

Benzodiazepines modulate GABA(A) function by binding at the interface between alpha (α) and gamma (γ) subunits. Of the 6 α-subunits, only 4 (α-1, -2, -3, and -5) participate in the formation of this binding site. The above target is a collection of all α- and γ-subunits that are known to participate in the formation of the benzodiazepine binding site.

### General Function

A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981)

### Specific Function

1,8-cineole 2-exo-monooxygenase activity

### Gene Name

CYP3A4

### Uniprot ID

P08684

### Uniprot Name

Cytochrome P450 3A4

### Molecular Weight

57342.67 Da

`,
  "protestkit": `{
  "url": "https://drugs.tripsit.me/prazepam",
  "experiencesUrl": "https://www.reddit.com/search/?q=Prazepam",
  "name": "Prazepam",
  "aliases": [
    "centrac",
    "centrax",
    "demetrin",
    "lysanxia",
    "pozapam",
    "prasepine",
    "prazene",
    "reapam",
    "trepidan"
  ],
  "aliasesStr": "centrac,centrax,demetrin,lysanxia,pozapam,prasepine,prazene,reapam,trepidan",
  "summary": "Benzodiazepine dervative. Has all the normal benzodiazepine-like quality (Anxiolytic/anticonvulsant/sedative/Skeletal muscle relaxant) It is also a prodrug for Desmethyldiazepam which is responsible for most if not all of the effects of Prazepam.",
  "reagents": null,
  "classes": {
    "chemical": [],
    "psychoactive": [
      "SSRI"
    ]
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Light",
          "value": "5-10mg"
        },
        {
          "name": "Common",
          "value": "10-20mg"
        },
        {
          "name": "Strong",
          "value": "20-40mg."
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.75 - 2.0 hours"
        },
        {
          "name": "Duration",
          "value": "8.0 - 20.0 hours"
        },
        {
          "name": "After effects",
          "value": "8.0 - 24.0 hours"
        }
      ]
    }
  ],
  "interactions": [
    {
      "name": "2C-T-x",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "2C-x",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "5-MeO-xxT",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Alcohol",
      "status": "Dangerous"
    },
    {
      "name": "Amphetamines",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Caffeine",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Cannabis",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Cocaine",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DMT",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DOx",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DXM",
      "status": "Caution"
    },
    {
      "name": "GHB/GBL",
      "status": "Dangerous"
    },
    {
      "name": "Gabapentinoids",
      "status": "Unsafe"
    },
    {
      "name": "Ketamine",
      "status": "Caution"
    },
    {
      "name": "LSD",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MAOIs",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "MDMA",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MMC class",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MXE",
      "status": "Caution"
    },
    {
      "name": "Mescaline",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Mushrooms",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "NBOMes",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Nitrous",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Opioids",
      "status": "Dangerous"
    },
    {
      "name": "PDA5",
      "status": "Caution"
    },
    {
      "name": "PVP class",
      "status": "Unsafe"
    },
    {
      "name": "Poppers",
      "status": "Unsafe"
    },
    {
      "name": "SSRIs",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Tramadol",
      "status": "Dangerous"
    }
  ],
  "effects": "Anxiolytic, Anticonvulsant, Sedative, Skeletal Muscle Relaxant",
  "categorized_effects": {
    "Physical effects": [
      "Anticonvulsant",
      "Sedative",
      "Skeletal Muscle Relaxant"
    ],
    "Mental effects": [
      "Anxiolytic"
    ],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "tripsit-factsheets": `# Prazepam
*Source: TripSit Factsheets (tripsit.me)*

## Summary

Benzodiazepine dervative. It is suggested to have effects typical to common benzodiazepines such as anxiolytic, anticonvulsant, sedation, and skeletal muscle relaxant. It is a prodrug for desmethyldiazepam which is suggested to be the causer of the majority, if not all of the effects to prazepam.

## Classification
- **Categories:** benzodiazepine, depressant, habit-forming
- **Also known as:** centrac, centrax, demetrin, lysanxia, pozapam, prasepine, prazene, reapam, trepidan

## Dosage

### Oral
- **Common:** 10-20mg
- **Light:** 5-10mg
- **Strong:** 20-40mg.

## Duration
- **Onset:** 45-120 minutes
- **Duration:** 8-20 hours
- **After Effects:** 8-24 hours

## Effects
- Anxiolytic
- Anticonvulsant
- Sedative
- Skeletal Muscle Relaxant

## Additional Information
- **Avoid:** All other CNS depressants, and Cimetidine
`,
  "wikipedia": `# Prazepam
*Source: https://en.wikipedia.org/wiki/Prazepam*

Prazepam is a benzodiazepine derivative drug developed by Warner-Lambert in the 1960s. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Prazepam, (Elimination half-life 29-224h), is a prodrug for desmethyldiazepam, (Elimination half-life 36-200h), which is responsible for the therapeutic effects of prazepam.

## Indications

Prazepam is indicated for the short-term treatment of anxiety. After short-term therapy, the dose is usually gradually tapered-off to reduce or avoid any withdrawal or rebound effects. Desmethyldiazepam, an active metabolite, has a very long half-life of 36 to 200 hours, which contributes to the therapeutic effects of prazepam.

## Side effects

Side effects of prazepam are less profound than with other benzodiazepines. Excessive drowsiness and with longer-term use, drug dependence, are the most common side effects of prazepam. Side effects such as fatigue or "feeling spacey" can also occur but less commonly than with other benzodiazepines. Other side effects include feebleness, clumsiness or lethargy, clouded thinking and mental slowness.

## Tolerance, dependence and withdrawal

Tolerance and dependence can develop with long-term use of prazepam, and upon cessation or reduction in dosage, then a benzodiazepine withdrawal syndrome may occur with symptoms such as tremulousness, dysphoria, psychomotor agitation, tachycardia and sweating. In severe cases, hallucinations, psychosis and seizures can occur. Withdrawal-related psychosis is generally unresponsive to antipsychotic mediations. The risk and severity of the withdrawal syndrome increases the higher the dose and the longer prazepam is taken for. Tolerance, dependence and withdrawal problems may be less severe than with other benzodiazepines, such as diazepam. It may be because tolerance is slower to develop with prazepam than with other benzodiazepines. Abrupt or over-rapid discontinuation of prazepam after long-term use, even at low dosage, may result in a protracted withdrawal syndrome.
Benzodiazepines can induce serious problems of addiction, which is one of the main reasons for their use being restricted to short-term use. A survey in Senegal found that the majority of doctors believed that their training in this area was generally poor. It was recommended that national authorities take urgent action regarding the rational use of benzodiazepines. Almost one-fifth of doctors ignored prescription guidelines regarding short-term use of benzodiazepines, and almost three-quarters of doctors regarded their training and knowledge of benzodiazepines to be inadequate. More training regarding benzodiazepines has been recommended for doctors.

## Contraindications and special caution

Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with comorbid psychiatric disorders.

## Mechanism of action

Prazepam exerts its therapeutic effects primarily via modulating the benzodiazepine receptor which in turn enhances GABA function in the brain. Prazepam like other benzodiazepines has anticonvulsant properties, but its anticonvulsant properties are not as potent as other benzodiazepines when tested in animal studies.

## Pharmacokinetics

Prazepam is metabolised into descyclopropylmethylprazepam (also known as desmethyldiazepam) and 3-hydroxyprazepam which is further metabolised into oxazepam. Prazepam is a prodrug for descyclopropylmethylprazepam/desmethyldiazepam (also known as norprazepam or nordazepam) which is responsible for most of the therapeutic activity of prazepam rather than prazepam itself.

## Interactions

Prazepam may interact with cimetidine. Alcohol in combination with prazepam increases the adverse effects, particularly performance impairing side effects and drowsiness.

## Overdose

The symptoms of an overdose of prazepam include sleepiness, agitation and ataxia. Hypotonia may also occur in severe cases. Overdoses in children typically result in more severe symptoms of overdose.

## Abuse potential

Prazepam like other benzodiazepines has abuse potential and can be habit forming. However, its abuse potential may be lower than other benzodiazepines because it has a slow onset of action.

## Toxicity

Animal studies have found prazepam taken during pregnancy results in delayed growth and causes reproductive abnormalities.

## Trade names

Common trade names include Centrac, Centrax, Demetrin, Lysanxia, Mono Demetrin, Pozapam, Prasepine, Prazene, Reapam and Trepidan. Trade names vary depending on the country; Austria: Demetrin, Belgium: Lysanxia, France: Lysanxia, Germany: Demetrin; Mono Demetrin, Greece: Centrac, Ireland: Centrax, Italy: Prazene; Trepidan, Macedonia: Demetrin, Prazepam, Netherlands: Reapam, Portugal: Demetrin, South Africa: Demetrin, Switzerland: Demetrin, Thailand: Pozapam; Prasepine.
`,
};
